R&G PharmaStudies Co., Ltd. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 468.19 million compared to CNY 442.35 million a year ago. Revenue was CNY 468.19 million compared to CNY 442.35 million a year ago.

Net income was CNY 83.84 million compared to CNY 70.63 million a year ago. Basic earnings per share from continuing operations was CNY 1.0813 compared to CNY 0.9813 a year ago. Diluted earnings per share from continuing operations was CNY 1.0813 compared to CNY 0.9813 a year ago.